Kamada (KMDA) Interest & Investment Income (2012 - 2026)
Kamada (KMDA) posted quarterly Interest & Investment Income of $425000.0 for Q1 2026, down 20.41% year-on-year from $534000.0 in Q1 2025, and down 3.85% on a QoQ basis from $442000.0 in Q4 2025.
Kamada (KMDA) Interest & Investment Income (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Interest & Investment Income for 15 consecutive years, with $425000.0 the latest figure, recorded in Q1 2026.
- Quarterly Interest & Investment Income fell 20.41% year-over-year to $425000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 27.09% YoY) and the FY2025 annual result came in at $1.9 million, down 9.3% from the prior year.
- Interest & Investment Income declined to $425000.0 in Q1 2026 per KMDA's latest filing, from $442000.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for KMDA reached as high as $684000.0 in Q4 2024 and fell as low as -$88000.0 in Q2 2023.
- A 5-year average of $237706.8 and a median of $67000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income sank 8900.0% — and 2024, when it jumped 1119900.0%.
- Year by year, Interest & Investment Income stood at $59000.0 in 2022, then surged by 740.68% to $496000.0 in 2023, then surged by 37.9% to $684000.0 in 2024, then tumbled by 35.38% to $442000.0 in 2025, then declined by 3.85% to $425000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $425000.0, $442000.0, and $492000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Kamada | 399.49 Mn | 326.34 Mn | 19.12 Mn | 425,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 425,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Sep 30, 2025 | 492,000.00 |
| Jun 30, 2025 | 453.00 |
| Mar 31, 2025 | 534,000.00 |
| Dec 31, 2024 | 684,000.00 |
| Sep 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 508.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 496,000.00 |
| Sep 30, 2023 | 67,000.00 |
| Jun 30, 2023 | -88,000.00 |
| Mar 31, 2023 | 25.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 29.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 18,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | 99,000.00 |